Kennedy Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Kennedy Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,222	Closed	-$1.11M	–	672
2025 Q1	$1.11M	Sell	25,222 -53,130	-68%	-$2.45M	0.03%	497
2024 Q4	$2.83M	Buy	78,352 +3,653	+5%	+$128K	0.06%	448
2024 Q3	$2.39M	Buy	74,699 +29,819	+66%	+$1.11M	0.05%	480
2024 Q2	$1.69M	Buy	44,880 +40,350	+891%	+$1.7M	0.04%	530
2024 Q1	$223K	Sell	4,530 -25,475	-85%	-$1.18M	﹤0.01%	698
2023 Q4	$1.1M	Sell	30,005 -6,735	-18%	-$176K	0.02%	578
2023 Q3	$849K	Hold	36,740	–	–	0.02%	579
2023 Q2	$963K	Hold	36,740	–	–	0.02%	557
2023 Q1	$946K	Hold	36,740	–	–	0.03%	494
2022 Q4	$956K	Buy	+36,740	New	+$905K	0.03%	497

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Kennedy Capital Management's SWTX Position: Q2 2025 in Review

Kennedy Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 25,222 shares — an estimated $1.11M sold.

Kennedy Capital Management first reported a position in SWTX in Q4 2022 and held it in 10 quarters. The position peaked at $2.83M in Q4 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Kennedy Capital Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Kennedy Capital Management sold 25,222 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.11M.
Kennedy Capital Management first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 10 quarters.
Kennedy Capital Management's SpringWorks Therapeutics position peaked at $2.83M in Q4 2024.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Kennedy Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.